27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Also, we performed analyses including only trials in which an increase in the cardiovascular fitness of participants had been demonstrated. 5 key findings →
Participants: 754 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Studies are heterogeneous in many aspects, including size sample, intervention, and instruments of measures. 3 key findings →
Design: systematic review Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
Cognitive-motor dual-task training was more beneficial than single-task training alone in improving broader domains of cognitive functions of elderly persons, and the improvement was not directly due to modulating Aβ metabolism. 4 key findings →
Participants: 27 Evidence: high
Full summary, score breakdown and related studies → Original source
Impaired odor identification, particularly in the anosmic range, is associated with increased mortality in older adults even after controlling for dementia and medical comorbidity. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Epilepsy is highly prevalent in people with intellectual disabilities. 1 key finding →
Design: systematic review Participants: 48 Evidence: high
Full summary, score breakdown and related studies → Original source
Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function. 5 key findings →
Participants: 89 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. 4 key findings →
Participants: 3,232 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The best CSF measures for identifying MCI-AD were Aβ42/total tau (t-tau) and Aβ42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). 3 key findings →
Design: longitudinal study Participants: 122 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study showed that subcutaneous etanercept (50 mg/wk) was well tolerated in this small group of patients with Alzheimer disease dementia, but a larger more heterogeneous group needs to be tested before recommending its use for broader groups of patients. 4 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The Mini-Mental State Examination (MMSE) is the best-known and the most often used short screening tool for providing an overall measure of cognitive impairment in clinical, research and community settings. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
As tau aggregation pathology correlates with clinical dementia in Alzheimer's disease (AD), a tau aggregation inhibitor (TAI) could have therapeutic utility. 4 key findings →
Participants: 135 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The HBA-CT program improves cognitive, mood, and sleep functions in older adults 'at risk' of dementia, and therefore offers promise as a secondary prevention strategy. 1 key finding →
Participants: 64 Evidence: high
Full summary, score breakdown and related studies → Original source
Increasing research has evidenced that our brain retains a capacity to change in response to experience until late adulthood. 3 key findings →
Design: longitudinal study Participants: 109 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Posttraumatic stress disorder (PTSD) is a debilitating condition associated with mild to moderate cognitive impairment and with a prevalence rate of up to 22% in veterans. 5 key findings →
Design: systematic review Participants: 846 Evidence: high
Full summary, score breakdown and related studies → Original source
The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia. 4 key findings →
Design: meta-analysis Participants: 199 Evidence: high
Full summary, score breakdown and related studies → Original source
Our results corroborate the positive effect of pb-CT and its maintenance primarily on memory in HE and MCI participants that did not seem to be potentiated by RT. 5 key findings →
Participants: 348 Evidence: high
Full summary, score breakdown and related studies → Original source
Compared with respective matched nonusers, individuals receiving haloperidol had an increased mortality risk of 3.8% (95% CI, 1.0%-6.6%; P Conclusions and relevance The absolute effect of antipsychotics on mortality in elderly patients with dementia may be higher than previously reported and increases with dose. 5 key findings →
Design: case-control study Participants: 90,786 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population. 3 key findings →
Design: open-label trial Participants: 176 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Health care expenditures among persons with dementia were substantially larger than those for other diseases, and many of the expenses were uncovered (uninsured). 1 key finding →
Design: retrospective cohort Participants: 1,702 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this study, quantitative results were inconclusive owing to small sample size. 5 key findings →
Design: randomized controlled trial Participants: 25 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Using stratification with simply assessed markers, it is now not only possible, but practical to include patients with RBD in neuroprotective trials against Parkinson disease, multiple system atrophy, and dementia with Lewy bodies. 3 key findings →
Design: prospective cohort Participants: 89 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a progressive syndrome of global cognitive impairment with significant health and social care costs. 4 key findings →
Design: meta-analysis Participants: 9,422 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
21% (7065) of the cohort had a record of mental illness at study entry, 25% (8300) had a record of challenging behaviour, and 49% (16,242) had a record of prescription of psychotropic drugs. 5 key findings →
Design: cohort study Participants: 33,016 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Scale of benefit is comparable with in-person training, indicating its potential as a public health intervention. 3 key findings →
Design: randomized controlled trial Participants: 2,912 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Besides the MMSE, there are many other tests with comparable diagnostic performance for detecting dementia. 4 key findings →
Participants: 102 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →